4.3.2004
EN
Official Journal of the European Union
L 66/41
ANNEX II
ESSENTIAL MEDICAL USES
Quota of controlled substances of group I that may be used in the production of metered-dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:
3M (UK)
Aventis (UK)
Bespak (UK)
Boehringer Ingelheim (D)
Chiesi (I)
Glaxo Smith Kline (UK)
IG Sprühtechnik (D)
IVAX (IRL)
Jaba Farmaceutica (P)
Lab. Aldo-Union (E)
Inyx Pharmaceuticals (UK)
Otsuka Pharmaceuticals (E)
Schering-Plough (B)
Sicor (I)
Valeas (I)
Valois (F)
VARI (I)
